Literature DB >> 8683697

The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men.

C S Cooper1, J H MacIndoe, P J Perry, W R Yates, R D Williams.   

Abstract

PURPOSE: We evaluated the effect of exogenous testosterone administration on serum total and free prostate specific antigen (PSA) in healthy young men.
MATERIALS AND METHODS: Nine volunteers received either 100, 250 or 500 mg. testosterone by intramuscular injection each week for 15 weeks. Blood was drawn every other week for 28 weeks and at week 40. Serum total and free PSA, and total and free testosterone were measured and compared to baseline values.
RESULTS: Significant elevations in total and free testosterone occurred but no significant change in serum total and free PSA was detected.
CONCLUSIONS: Serum PSA is not responsive to elevated serum testosterone levels in healthy young men. PSA metabolism in the normal prostate is unclear but our findings may have implications for differentiation of pathological conditions of the human prostate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683697     DOI: 10.1097/00005392-199608000-00028

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

Review 1.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

Review 2.  Hypogonadism and its treatment among prostate cancer survivors.

Authors:  Edward J Choi; Perry Xu; Farouk M El-Khatib; Linda M Huynh; Faysal A Yafi
Journal:  Int J Impot Res       Date:  2020-12-12       Impact factor: 2.896

Review 3.  Update on Testosterone Replacement Therapy in Hypogonadal Men.

Authors:  Kevin Matthew Yen Bing Leung; Khalid Alrabeeah; Serge Carrier
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

4.  Association between Serum Testosterone and PSA Levels in Middle-Aged Healthy Men from the General Population.

Authors:  Saad Elzanaty; Babak Rezanezhad; Gert Dohle
Journal:  Curr Urol       Date:  2017-03-30

Review 5.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

6.  Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer.

Authors:  Eric K Oermann; Simeng Suy; Heather N Hanscom; Joy S Kim; Sue Lei; Xia Yu; Guowei Zhang; Brook Ennis; Joyann P Rohan; Nathaniel Piel; Benjamin A Sherer; Devin Borum; Viola J Chen; Gerald P Batipps; Nicholas L Constantinople; Stephen W Dejter; Gaurav Bandi; John Pahira; Kevin G McGeagh; Lucile Adams-Campbell; Reena Jha; Nancy A Dawson; Brian T Collins; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  J Hematol Oncol       Date:  2011-03-27       Impact factor: 17.388

Review 7.  Serum testosterone level, testosterone replacement treatment, and prostate cancer.

Authors:  Ali Atan; Altug Tuncel; Suleyman Yesil; Derya Balbay
Journal:  Adv Urol       Date:  2013-09-18

Review 8.  Androgens and prostate disease.

Authors:  Lori A Cooper; Stephanie T Page
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

Review 9.  Shifting the Paradigm of Testosterone Replacement Therapy in Prostate Cancer.

Authors:  Michael A Bell; Jeffrey D Campbell; Gregory Joice; Nikolai A Sopko; Arthur L Burnett
Journal:  World J Mens Health       Date:  2018-03-22       Impact factor: 5.400

10.  Testosterone replacement and prostate cancer.

Authors:  Ranjith Ramasamy; Erik S Fisher; Peter N Schlegel
Journal:  Indian J Urol       Date:  2012-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.